Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that coadministration of finasteride and tamsulosin in healthy Chinese males appears unlikely to result in a clinically significant pharmacokinetic interaction.

This review explores the potential of topical minoxidil as a treatment for erectile dysfunction, indicating that while a mild erectile response was observed, evidence remains insufficient for confirmation.

This study introduced and validated new spectrophotometric methods to simultaneously determine finasteride and tadalafil in Entadfi™ capsules with high sensitivity and without interference from excipients.

This source reports that in men treated with 5α-reductase inhibitors for androgenetic alopecia, sexual adverse events such as decreased libido and erectile dysfunction occurred at rates from 1.9% to 12% in clinical trials, with effects often being mild and reversible upon stopping treatment.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

This study found a significant association between finasteride use and reports of sexual dysfunction, particularly greater in young men using it for alopecia compared to older BPH patients.

This study found that combining α 1A-blockers with Prozac was more effective for treating premature ejaculation than using Prozac alone.

This study found that terazosin hydrochloride, when used with finasteride, improved prostate volume and lowered blood pressure in BPH patients with high blood pressure, although the overall treatment effect was not significantly different from controls.

This narrative review discusses the mixed and evolving evidence regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their influence on erectile dysfunction in men with type 2 diabetes and obesity, highlighting potential benefits and concerns yet to be clarified.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

This study found that men taking 1 mg/day of finasteride had significantly reduced sperm production and morphology but similar hormonal, sexual, and psychological profiles compared to controls, suggesting finasteride affects semen quality without altering other physiological functions.

This review discusses the management options for recurrent ischemic priapism, noting that ketoconazole, finasteride, and other hormonal therapies may be effective but can have significant side effects; it reports no new clinical findings.

This study found that finasteride reduces microvascular density and VEGF expression in the seminal vesicle tissue of rats.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

This article reviews the management of excessive pre-ejaculate, highlighting case reports where 5-α-reductase inhibitors, such as finasteride and dutasteride, led to symptom resolution in patients reporting distress due to this condition.

This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.

This study found that finasteride treatment may decrease contraction of seminal vesicle tissue and alter some semen parameters in male rabbits.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This article reviews the use of 5alpha-reductase inhibitors for managing benign prostatic hyperplasia and reports no new clinical results.

This study found no significant difference in the risk of poor glycemic control between men with type 2 diabetes using tamsulosin and those using finasteride.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.

This article discusses the MaasaLong male enhancement supplement, which claims to improve erectile dysfunction and overall male health but provides no new empirical results.

In this study, researchers created a coamorphous system combining tadalafil and finasteride that demonstrated improved solubility, dissolution, and stability compared to their physical mixture, offering potential therapeutic advantages for benign prostatic hyperplasia.

This study successfully applied an optimized LC-MS/MS method for accurately determining finasteride concentrations and assessing its pharmacokinetics in healthy volunteers.